Has Frederick Goldman received payments from drug or device companies?

Yes. Drug and device makers reported $75,715 in general payments to Frederick Goldman across 98 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Frederick Goldman did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Frederick Goldman come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Frederick Goldman

Pediatric Hematology-Oncology · Birmingham, ALNPI 1124013826

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $61,402 of the $75,715 with a category attached, or 81.1%. Jazz Pharmaceuticals Inc. accounts for 92.2% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $31,673 and has fallen 85.4% since, to $4,610 in 2025. Among pediatric hematology-oncology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$75,715in general payments, 2019–2025

Across 98 payments — averaging $772.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Jazz Pharmaceuticals Inc.$70K
Vertex$3K
Omeros Corporation$3K
AstraZeneca$353
Astellas Pharma US Inc$70
Amgen$31
plus $33 from 2 others

$162,467in research payments, 2019–2025

Across 25 payments — averaging $6498.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Jazz Pharmaceuticals Inc.$110K
AstraZeneca$39K
Astellas Pharma Global Development$13K

What the payments were for

Consulting fees$2,8254%
Speaking & faculty fees$61,40281%
Travel & lodging$8,86312%
Food & beverage$2,5563%
Education$700%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Jazz Pharmaceuticals Inc.	84	$69,783
Vertex	6	$2,825
Omeros Corporation	1	$2,620
AstraZeneca	2	$353
Astellas Pharma US Inc	1	$70
Amgen	2	$31
Syndax Pharmaceuticals, Inc.	1	$17
Novartis	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$75,715 in reported general payments places this provider in the 90th percentile of 38 pediatric hematology-oncology providers in Alabama.

See all pediatric hematology-oncology providers in Alabama →

Other pediatric hematology-oncology in Birmingham

Julie Kanter WashkoBirmingham$273K
Aman WadhwaBirmingham$100K
Jeffrey LebensburgerBirmingham$57K
Joseph ChewningBirmingham$5K
Laura MetrockBirmingham$3K
Todd CooperBirmingham$2K
Chibuzo IlonzeBirmingham$2K
Loretta ParkerBirmingham$1K
Thomas HowardBirmingham$767
Ana XavierBirmingham$514

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →